19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor: Progressive disseminated histoplasmosis (PDH) of infancy occurs most commonly in previously healthy infants <1 year of age, typically after exposure to a large fungal inoculum ( 1 ). Even with treatment, the disease is fatal in ≈13% of cases ( 1 ). Common symptoms include fever, hepatosplenomegaly, lymphadenopathy, and failure to thrive. Laboratory abnormalities frequently include cytopenia and coagulopathy ( 1 , 2 ). Many clinical manifestations of PDH overlap with those of the hyperinflammatory condition hemophagocytic lymphohistiocytosis (HLH), and co-existence of HLH and histoplasmosis has been reported in adults. We report a case of simultaneous PDH and HLH in an infant. A 6-month-old African American girl was brought for treatment to St. Jude Children’s Research Hospital in April 2015 with a 1-month history of daily fever. Her history was notable only for a methicillin-resistant Staphylococcus aureus skin abscess diagnosed when she was 5 months old; it was drained, and she received oral clindamycin. On initial evaluation, she had fever, lethargy, and hepatosplenomegaly. Laboratory testing showed pancytopenia and mild hepatitis, and abdominal ultrasound confirmed hepatosplenomegaly. After admission, respiratory distress developed due to worsening hepatosplenomegaly. Additional laboratory testing revealed elevated ferritin (1,218 ng/mL; reference 10–100 ng/mL), low fibrinogen level (78 mg/dL; reference 185–443 mg/dL), elevated triglycerides (378 mg/dL; reference 0–149 mg/dL) and elevated soluble interleukin-2 receptor (21,530 pg/mL; reference <1,033 pg/mL). An HIV serologic test result was negative. Histologic examination of bone marrow showed many activated macrophages, including some with hemophagocytosis (Technical Appendix). On the basis of clinical and laboratory findings, the patient received a diagnosis of HLH, and treatment was initiated with etoposide and dexamethasone. Further evaluation of the bone marrow sample demonstrated fungal elements characteristic of Histoplasma capsulatum (Technical Appendix). Histoplasma antigen assays on serum and urine samples were positive for H. capsulatum above the limit of quantification. Histoplasma complement-fixation antibody titers for both yeast and mycelial antigens were negative, but immunodiffusion antibody tests for H and M bands were positive. Cerebrospinal fluid was also positive for Histoplasma antigen. Results of magnetic resonance imaging of the patient’s brain were normal for age. Because the patient’s condition met diagnostic criteria for both HLH and PDH, she was given etoposide, dexamethasone, and liposomal amphotericin B (LAmB), according to treatment guidelines for both conditions ( 3 , 4 ). Supportive care included transfusion of packed red blood cells, platelets, cryoprecipitate, and fresh frozen plasma. Her fever resolved after 10 days, and other symptoms resolved after 2 weeks. After 16 days of hospitalization, she was discharged to complete a 6-week course of LAmB with a plan to transition to oral itraconazole and complete 1 year of therapy, according to guidelines of the Infectious Diseases Society of America ( 4 ). HLH is a rare disease, characterized by impaired function of natural killer and cytotoxic T-lymphocytes that results in an unchecked inflammatory response. If not treated promptly, HLH can progress rapidly to multiorgan failure and death ( 3 ). HLH is categorized into familial or secondary forms. Familial HLH is caused by mutations in >1 of the genes required for perforin-dependent lymphocyte cytotoxicity; secondary HLH occurs in a person who does not have genetic risk factors ( 3 ). Both forms can be triggered by infection or malignancy ( 3 ). Diagnosis of HLH is based on clinical assessment (Table); no definitive diagnostic test exists ( 6 ). Initial treatment of HLH involves the use of corticosteroids, etoposide, or other drugs to block the hyperinflammatory response and specific therapy for the inciting infection if available ( 7 ). In some cases, in which a treatable inciting infection is identified, antimicrobial drug therapy alone might be sufficient. However, concurrent immunosuppressive therapy is usually recommended, especially for patients who are critically ill or whose condition is clinically deteriorating ( 3 ). Table Diagnostic criteria for HLH* Criterion HLH reference Patient in this report Fever ≥38.5°C 40°C† Splenomegaly Present Present† Cytopenia, 2 of 3 lineages ANC, cells/mm3 <1,000 1,500 Hemoglobin, g/dL <9 5.9† Platelet count, × 103/μL <100 11† Low fibrinogen, mg/dL <150 78†   or High triglycerides, mg/dL >265 fasting 378† Hemophagocytosis Present Present† NK cell activity Low or absent Normal Elevated ferritin, ng/mL >500 317 (max 1,218)† Soluble IL-2 receptor, pg/mL >2,400 21,530† *ANC, absolute neutrophil count; HLH, hemophagocytic lymphohistiocytosis; IL-2, interleukin-2; NK, natural killer. 
†Criteria met by this patient. The HLH-2004 diagnostic criteria require either a molecular/genetic diagnosis consistent with HLH or fulfillment of 5 of the 8 criteria shown. Adapted from (5). Many clinical manifestations of disseminated histoplasmosis, including prolonged fever, hepatosplenomegaly, pancytopenia, and coagulopathy, overlap with those of HLH. Because of the similarity in manifestations, differentiating these 2 conditions is challenging without specialized testing. Furthermore, laboratory tests specific for HLH, such as measuring soluble interleukin-2 receptor, have not been investigated in patients with isolated PDH, so whether they distinguish between the 2 conditions is unclear. To add further complexity, coexisting histoplasmosis and HLH has been described in several adult patients ( 5 , 8 – 10 ). However, whether HLH identification and adjunctive immunosuppressive therapy leads to improved outcomes in this situation is unknown. On the basis of our investigation of this infant with HLH and PDH, we recommend that all infants exhibiting HLH in Histoplasma-endemic regions be assessed for histoplasmosis. In addition, the similarity with the clinical features of PDH and the difficulty in diagnosis of HLH without specialized testing raise the question of whether a large number of infants with PDH would also meet the diagnostic criteria for HLH. If so, currently poor outcomes of PDH might be related to co-existing HLH with failure to control the inflammatory response, and the outcomes could be improved by diagnosis and simultaneous treatment of both conditions. Further research is needed to investigate this phenomenon. Technical Appendix Wright-Giemsa stain of the bone marrow biopsy specimen of a 6-month-old girl with hemophagocytic lymphohistiocytosis and progressive disseminated histoplasmosis.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.

          Evidence-based guidelines for the management of patients with histoplasmosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 30:688-95). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. New information, based on publications from the period 1999-2006, are incorporated into this guideline document. In addition, the panel added recommendations for management of histoplasmosis in children for those aspects that differ from aspects in adults.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Histoplasmosis-associated hemophagocytic syndrome: a case report.

            Hemophagocytic syndrome is a macrophage disorder that may develop as a result of immunological activation, such as that seen in severe infection. It has been described in persons with HIV/AIDS and in those with a variety of HIV-associated opportunistic infections, including those caused by Histoplasma capsulatum. If present, this disorder may portend a poorer prognosis. We describe an HIV-positive person in whom histoplasmosis-associated hemophagocytic syndrome was successfully treated.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Disseminated histoplasmosis: a cause of infection-associated hemophagocytic syndrome.

              We report a case of infection-associated hemophagocytic syndrome in the setting of disseminated histoplasmosis.
                Bookmark

                Author and article information

                Journal
                Emerg Infect Dis
                Emerging Infect. Dis
                EID
                Emerging Infectious Diseases
                Centers for Disease Control and Prevention
                1080-6040
                1080-6059
                June 2016
                : 22
                : 6
                : 1119-1121
                Affiliations
                [1]St. Jude Children’s Research Hospital, Memphis, Tennessee, USA (K. Ferguson-Paul, S. Mangum, A. Porter, V. Leventaki, P. Campbell, J. Wolf);
                [2]University of Tennessee Health Sciences Center, Memphis (K. Ferguson-Paul, S. Mangum, A. Porter, J. Wolf)
                Author notes
                Address for correspondence: Joshua Wolf, St. Jude Children’s Research Hospital, Department of Infectious Diseases, 262 Danny Thomas Pl, Memphis, TN 38105, USA; email: joshua.wolf@ 123456stjude.org
                Article
                15-1682
                10.3201/eid2206.151682
                4880106
                27191972
                71a3b311-9a9e-4463-b04c-d54624bbb13b
                History
                Categories
                Letters to the Editor
                Letter
                Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis

                Infectious disease & Microbiology
                infant,histoplasmosis,lymphohistiocytosis,hemophagocytic,rare diseases,fungi,suggested citation for this article: ferguson-paul k,mangum s,porter a,leventaki v,campbell p,wolf j. hemophagocytic lymphohistiocytosis in infant with progressive disseminated histoplasmosis. emerg infect dis. 2016 jun [date cited]. http://dx.doi.org/10.3201/eid2206.151682

                Comments

                Comment on this article